Stories

For the hundreds of children diagnosed with pediatric low-grade glioma (pLGG) across Europe each year, the journey is rarely what families expect. It is often long, complex, and life-altering. However today, we’re excited that the treatment landscape has progressed.  

In the pharmaceutical industry, it’s easy to focus on data, strategy, and performance metrics. But behind every decision are real people. For Guillermo Castillo Acero, Head of European Mid-Sized Markets at Ipsen, that reality became clear during a precise moment in his career.

For too long, modern medicine has treated diseases as if they were uniform, defined by a label rather than by their underlying biology. Today, we have an unprecedented ability to interrogate the molecular drivers that shape each person’s cancer, and in doing so, we’re transforming how we diagnose, develop and deliver the medicines that matter most.

At the heart of Ipsen’s early discovery efforts is a question of fit—how a molecule interacts with a disease-relevant protein, and what that means for therapeutic potential. Alexis Cocozaki’s team focuses on that exact space, applying biophysical and structural biology techniques to evaluate and optimize new assets at the atomic level. 

We are pleased to announce that Ipsen’s 2025 Sustainability Statement – our annual publication outlining Ipsen’s environmental, social and governance (ESG) commitments, progress and priorities – is now available on our website, reflecting our commitment to maximize positive change for future generations.